Trial Profile

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
Indications Brain metastases; Breast cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Male breast cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Triple negative breast cancer
Focus Therapeutic Use

Most Recent Events

15 Apr 2025 Planned End Date changed from 30 Apr 2025 to 28 Feb 2028.
15 Apr 2025 Planned primary completion date changed from 30 Apr 2025 to 28 Feb 2028.
10 Apr 2024 According to Trial design presented at the 115th Annual Meeting of the American Association for Cancer Research, the first patient was enrolled in January 2022 and accrual of patients is ongoing

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com